Gene/Protein · 7 studies in the Atlas · also known as 4E-BP, 4EBP1, EIF4EBP1, PHAS-I
Translational repressor; the master effector through which mTORC1 controls protein synthesis. mTORC1 phosphorylates 4E-BP1 to release eIF4E and switch translation ON.
| Study | Year | Tier | Finding |
|---|
| SCH2025 | 2025 | B | First-in-human trial of a bi-steric mTORC1-selective inhibitor. Treatment-related hyperglycemia was low (4%) and not dose-limiting -- direct clinical confirmation that sparing mTORC2 avoids the metabo |
| MEN2023 | 2023 | C | RMC-6272, a bi-steric molecule with >25-fold selectivity for mTORC1 over mTORC2, completely suppresses mTORC1 (hitting the rapamycin-resistant substrate 4E-BP1) and overcomes hormone- and CDK4/6-inhib |
| ZID2009 | 2009 | C | Connected the dots between diet, mTOR, and lifespan. Dietary restriction lowers mTOR activity, which frees up 4E-BP - and here 4E-BP was shown to be REQUIRED for the lifespan boost, working by selecti |
| LAB2015 | 2015 | D | Explained HOW rapamycin calms 'inflammaging'. Senescent cells spew inflammatory signals (the SASP) that damage surrounding tissue and even feed tumors. mTOR powers this by translating IL1A, the cytoki |
| HSI2012 | 2012 | D | Showed WHY mTOR-driven translation matters for cancer: in prostate cancer, oncogenic mTOR selectively translates a specific set of pro-invasion mRNAs that drive metastasis. An ATP-competitive mTOR inh |
| THO2012 | 2012 | D | Used ribosome profiling with the complete inhibitor Torin1 to settle a long debate: mTORC1's translational control runs almost entirely through the 4E-BP family acting on a specific class of mRNAs (TO |
| THO2009 | 2009 | D | Dropped a bombshell: rapamycin does NOT fully block mTORC1. Using Torin1 (which jams the active site directly), the authors showed rapamycin leaves important mTORC1 jobs running - notably 4E-BP1 phosp |